Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

First Pulsed-Field Ablation System Gets FDA Approval

Todd Neale

December 14, 2023

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves First Extravascular ICD

Yael L. Maxwell

October 23, 2023

News Daily News

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

L.A. McKeown

September 12, 2023

News Daily News

Aveir DR Dual-Chamber Leadless Pacemaker Wins FDA Approval

L.A. McKeown

July 06, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Shelley Wood

June 05, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

Advertisement

Top Endovascular News of 2023

First Pulsed-Field Ablation System Gets FDA Approval

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves First Extravascular ICD

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

Aveir DR Dual-Chamber Leadless Pacemaker Wins FDA Approval

FDA Approves Colchicine for Decreasing CV Events

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content